Nature Communications (Jan 2023)
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
- Walid K. Chatila,
- Henry Walch,
- Jaclyn F. Hechtman,
- Sydney M. Moyer,
- Valeria Sgambati,
- David M. Faleck,
- Amitabh Srivastava,
- Laura Tang,
- Jamal Benhamida,
- Dorina Ismailgeci,
- Carl Campos,
- Fan Wu,
- Qing Chang,
- Efsevia Vakiani,
- Elisa de Stanchina,
- Martin R. Weiser,
- Maria Widmar,
- Rhonda K. Yantiss,
- Manish A. Shah,
- Adam J. Bass,
- Zsofia K. Stadler,
- Lior H. Katz,
- Ingo K. Mellinghoff,
- Nilay S. Sethi,
- Nikolaus Schultz,
- Karuna Ganesh,
- David Kelsen,
- Rona Yaeger
Affiliations
- Walid K. Chatila
- Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medicine
- Henry Walch
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Jaclyn F. Hechtman
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Sydney M. Moyer
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Valeria Sgambati
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
- David M. Faleck
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Amitabh Srivastava
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Laura Tang
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Jamal Benhamida
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Dorina Ismailgeci
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Carl Campos
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Fan Wu
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Qing Chang
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center
- Efsevia Vakiani
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Elisa de Stanchina
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
- Martin R. Weiser
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Maria Widmar
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Rhonda K. Yantiss
- Department of Pathology, Weill Cornell Medicine
- Manish A. Shah
- Department of Medicine, Weill Cornell Medicine
- Adam J. Bass
- Herbert Irving Comprehensive Cancer Research Center, Columbia University Irving Medical Center
- Zsofia K. Stadler
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Lior H. Katz
- Gastroenterology Institute, Sheba Medical Center, Tel Hashomer
- Ingo K. Mellinghoff
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Nilay S. Sethi
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Nikolaus Schultz
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Karuna Ganesh
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
- David Kelsen
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Rona Yaeger
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-022-35592-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 13
Abstract
Colitis-associated cancers (CACs) develop in patients with inflammatory bowel disease and have distinct genomic features compared to sporadic colorectal cancers. Here, the authors characterize the genomic alterations of CAC tumors and dysplasia, finding decreased Wnt signaling and a lack of shared early genetic steps.
